stride study semaglutide and walking capacity in symptomatic PAD and type 2 diabetes patients: the trial Data Deep Dive: The Latest

Roche has made a significant move by acquiring Carmot Therapeutics for $2.7 billion, following promising Phase I results for its own GLP-1/GIP receptor agonist

Awarded to a full-time DPT student who demonstrates outstanding academic achievement and financial need

NAIONs devastating impact extends far beyond visual acuity measurements, fundamentally altering patients ability to work, drive, read, and maintain independence

typically dose-related and diminishing over time Serious risks : Pancreatitis (rare), gallbladder events, thyroid C-cell tumor boxed warning (from rodent studies) Dose escalation : Slow titration (0.25 mg escalating monthly) mitigates GI tolerability Strength : The safety database is massive, with well-defined risk-benefit profile across multiple patient populations Survodutide Side Effects# Less well-characterized with limited clinical exposure: GI effects : Expected GLP-1 class effects (nausea, vomiting, diarrhea) observed in Phase 2 Glucagon-specific concerns : Potential for hepatic glucose output increase (mitigated by GLP-1 component), theoretical impact on blood glucose in diabetic populations Heart rate : Glucagon receptor agonism may affect heart rate